產(chǎn)品屬性：
產(chǎn)品名稱 | 規(guī)格 | CAS號 | 型號 |
COTI-2 | 5mg 10mg 25mg | 1039455-84-9 | EY-Y0165473 |
Cas No.1039455-84-9
別名
化學(xué)名 4-(2-pyridinyl)-2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide-1-piperazinecarbothioic acid
分子式 C19H22N6S
分子量 366.5
溶解度 ≤1mg/ml in DMSO;2.5mg/ml in dimethyl formamide
儲存條件 Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述：
p53 has varoius mechanisms of anticancer function and plays a critical role in genomic stability, apoptosis and inhibition of angiogenesis.
In vitro: Previous study tested the efficacy of COTI-2 against a diverse group of human cancer cell lines with different genetic mutation backgrounds. Results showed that COTI-2 efficiently inhibited the proliferation rate of all the tested cell lines following 72 h of treatment. Most cell lines showed nanomolar sensitivity to COTI-2 treatment. In addition, COTI-2 was significantly more effective at inhibiting tumor cell proliferation than either cetuximab or erlotinib in COLO-205, HCT-15, and SW620 cell lines. Notably, all three lines were insensitive to growth inhibition to any degree in response to low concentrations of cetuximab and erlotinib, but highly sensitive to even low doses of COTI-2 [1].
In vivo: The effects of COTI-2 on inhibiting the growth of HT-29 and SHP-77 xenografts in immunocompromised mice was assessed when intraperitoneally administered. It was found that COTI-2 at 10 mg/kg could significantly inhibit tumor growth in the HT-29 human colorectal tumor xenografts. In addition to reducing tumor volumes at specific times post-treatment, COTI-2 could also delay the time required for tumors to reach specified volumes [1].
Clinical trial: A study of COTI-2 for the treatment of advanced or recurrent gynecologic malignancies is currently recruiting patients [2].
References:
[1] Salim, K. Y.,Vareki, S.M.,Danter, W.R., et al. COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. Oncotarget 7(27), (2016).
[2] https://clinicaltrials. gov/ct2/show/NCT02433626term=COTI-2&rank=1
關(guān)鍵字： 1039455-84-9;C19H22N6S;COTI-2;
上海一研生物科技有限公司Shanghai yiyan bio-technology Co. Ltd.主要從事免疫學(xué)、分子生物學(xué)和常規(guī)生化試劑等為一體的科研產(chǎn)品銷售企業(yè)，公司自成立以來，秉承""全心全意服務(wù)于科研工作者""的企業(yè)理念，立足生物科技領(lǐng)域，運(yùn)用生物技術(shù)和科研試劑，發(fā)展現(xiàn)代生物科技，為各類大中小醫(yī)院及其它醫(yī)療機(jī)構(gòu)、高等院校、科研院所、企事業(yè)單位提供優(yōu)質(zhì)的產(chǎn)品，服務(wù)生物科技領(lǐng)域的科學(xué)研究人員。
公司具有對普通貨物、冷藏及冷凍倉庫的存儲、包裝及運(yùn)輸能力。
公司將始終堅持信譽(yù)立業(yè)、以人為本、質(zhì)量保證、誠信服務(wù)的宗旨，不斷拼搏，開拓進(jìn)取，與各界朋友攜手共創(chuàng)美好未來。